share_log

Delivra Health and Its Brands LivRelief (TM) and Dream Water (TM) Report Continued Improvement in Adjusted EBITDA(1) Results for First Quarter of Fiscal 2023

Delivra Health and Its Brands LivRelief (TM) and Dream Water (TM) Report Continued Improvement in Adjusted EBITDA(1) Results for First Quarter of Fiscal 2023

Delivra Health及其旗下品牌LivRelipment(TM)和Dream Water(TM)報告2023財年第一季度調整後的EBITDA(1)業績繼續改善
newsfile ·  2022/11/28 20:35

Vancouver, British Columbia--(Newsfile Corp. - November 28, 2022) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) (formerly, Harvest One Cannabis Inc.) ("Delivra Health" or the "Company") , a consumer packaged goods company uniquely positioned in the health and wellness sector, is pleased to announce its financial and operating results for the three months ended September 30, 2022.

温哥華,不列顛哥倫比亞省-(Newsfile Corp.-2022年11月28日)-Delivra Health Brands Inc.(TSXV:DHB)(OTCQB:DHBUF)(前身為嘉實一號大麻公司)(“Delivra Health“或”公司“),一家在健康和健康領域獨樹一幟的消費品包裝公司,很高興宣佈其截至2022年9月30日的三個月的財務和經營業績。

Management Commentary

管理評論

"The first quarter of fiscal 2023 reflects our continued progress of executing on our key objectives and creating shareholder value as we work towards achieving profitability. Despite a reduction in revenue this quarter due to the timing of customer ordering patterns, we improved our gross profit margin to 51% from 33%, in the comparable quarter last year. We also reduced selling, general and administrative ("SG&A") expenses by 30% and further improved our adjusted earnings before interest, taxes, depreciation and amortization ("Adjusted EBITDA")(1) to $(0.15) million from $(0.78) million in the same period last year, bringing our financial results closer to a breakeven position which is a milestone for a health and wellness company operating in a very competitive environment," said Gord Davey, President and Chief Executive Officer of Delivra Health.

2023財年第一季度反映了我們在努力實現盈利的同時,在執行關鍵目標和創造股東價值方面的持續進展。儘管本季度收入因客户訂購模式的時機而減少,但我們的毛利率從去年同期的33%提高到51%。我們還減少了銷售、一般和行政管理(SG&A)支出增加了30%,並進一步改善了我們調整後的利息、税項、折舊和攤銷前收益(調整後的EBITDA")(1)從去年同期的78萬美元增加到15萬美元,使我們的財務業績更接近盈虧平衡,這對一家在競爭非常激烈的環境中運營的健康和保健公司來説是一個里程碑,“Delivra Health首席執行官Gord Davey和總裁説。

Mr. Davey continued, "Furthermore, our team has increased the distribution of our Dream Water products by partnering with over 2,400 Casey's General Stores, as well as launching our new innovative six count gummies and Dream Water Immunity shots. We expect these initiatives to strengthen the Company's business in the coming quarters."

戴維先生繼續説:“此外,我們的團隊通過與超過2400家凱西百貨公司合作,以及推出創新的六數口香糖和夢水免疫針劑,擴大了我們夢幻水產品的分銷。我們預計這些舉措將在未來幾個季度加強公司的業務。”

Financial Highlights

財務亮點

  • Net revenue: For the three months ended September 30, 2022, net revenue was $1.73 million compared to $2.13 million in the same period in the prior year. The $0.40 million or 19% reduction in net revenue was mainly due to a reduction in the sales of Dream Water™ in the US, which was driven by the timing of customer ordering patterns.
  • 淨收入:在截至2022年9月30日的三個月裏,淨收入為173萬美元,而去年同期為213萬美元。淨收入減少40萬美元或19%,主要是由於美國Dream Water™的銷售額減少,這是由客户訂購模式的時機推動的。
  • Gross profit and gross profit margin: For the three months ended September 30, 2022, the Company reported gross profit of $0.88 million and a 51% gross profit margin compared to $0.71 million and a 33% gross profit margin from continued operations in same period last year. This increase is attributed to changes in the Company's customer and channel mix and operational improvements.
  • 毛利和毛利率:截至2022年9月30日的三個月,公司報告毛利為88萬美元,毛利率為51%,而去年同期持續運營的毛利率為71萬美元,毛利率為33%。這一增長歸因於公司客户和渠道組合的變化 和運營方面的改進。
  • Expenses including SG&A and excluding non-cash items: For the three months ended September 30, 2022, the Company reported expenses of $1.04 million compared to $1.49 million in the same period last year, representing a 30% reduction for the quarter from continued operations. The reduction is mainly driven by lower sales and marketing expenses to conserve cash.
  • 費用包括SG&A,不包括非現金項目:在截至2022年9月30日的三個月裏,該公司報告的支出為104萬美元,而去年同期為149萬美元,與持續運營相比,該季度的支出減少了30%。減少的主要原因是為了節省現金而降低了銷售和營銷費用。
  • Adjusted EBITDA(1): For the three months ended September 30, 2022, the Company reported Adjusted EBITDA of $(0.15) million compared to $(0.78) million in the same period last year, representing a $0.63 million or 80% year over year improvement from continued operations. This reduction is driven by management's efforts in focusing on margin improvement supported by efficient administrative and selling support functions.
  • 調整後的EBITDA(1):在截至2022年9月30日的三個月中,該公司報告的調整後EBITDA為15萬美元,而去年同期為78萬美元,與持續運營相比,同比增長63萬美元或80%。這一減少是由於管理層在高效的行政和銷售支持職能的支持下,專注於提高利潤率的努力。

Summary of Key Financial Results

主要財務結果摘要

For the quarter ended September 30
($000's, except share and per share amounts) 2022 2021
Continued operations:
Net revenue $1,729 $2,130
Cost of sales 840 1,421
Inventory write-down 10 -
Gross profit 879 709
Gross profit margin 51% 33%
Expenses excluding non-cash expenses 1,043 1,487
Depreciation and amortization and share-based compensation (370) (686)
Loss from operations before other (expense) income (534) (1,464)
Other (expense) income 153 10
Net loss from continuing operations (381) (1,454)
截至9月30日的季度
($000,不包括每股和每股金額) 2022 2021
持續運營:
淨收入 $1,729 $2,130
銷售成本 840 1,421
庫存減記 10 -
毛利 879 709
毛利率 51% 33%
不包括非現金費用的費用 1,043 1,487
折舊和攤銷與股份薪酬 (370) (686)
在其他(費用)收入之前的運營虧損 (534) (1,464)
其他(費用)收入 153 10
持續經營淨虧損 (381) (1,454)

Expenses exluding non-cash items

不包括非現金項目的費用

For the quarter ended September 30
($000's, except share and per share amounts) 2022 2021
General and administration $964 $1,075
Sales and marketing 79 412
Total 1,043 1,487
截至9月30日的季度
($000,不包括每股和每股金額) 2022 2021
一般事務及行政事務 $964 $1,075
銷售和市場營銷 79 412
總計 1,043 1,487

Adjusted EBITDA (non-IFRS measure)(1)

調整後的EBITDA(非國際財務報告準則計量)(1)

For the quarter ended September 30
($000's, except share and per share amounts) 2022 2021
Loss from operations $(534) $(1,464)
Inventory write-down 10 -
Depreciation and amortization 332 537
Share-based compensation 38 149
Adjusted EBITDA(1) (154) (778)
截至9月30日的季度
($000,不包括每股和每股金額) 2022 2021
運營虧損 $(534) $(1,464)
庫存減記 10 -
折舊及攤銷 332 537
基於股份的薪酬 38 149
調整後的EBITDA(1) (154) (778)

About Delivra Health Brands Inc.

關於Delivra Health Brands Inc.

Helping people take control of their health with alternative wellness solutions is what energizes the Delivra Health team! The Delivra Health portfolio features innovative brands like Dream Water™ and LivRelief™, which deliver relief from common everyday issues like chronic pain, anxiety, and sleeplessness. Delivra Health products have allowed millions of customers to reclaim their mobility, energy, and in turn, quality of life. The websites of the Company's two subsidiaries are  Dream Water™ and  LivReliefTM. For more information, please visit  .

幫助人們通過替代健康解決方案控制自己的健康是Delivra Health團隊的動力所在!德利夫拉健康產品組合以創新品牌為特色,如夢想之水™和生活救濟™,這些品牌可以緩解常見的日常問題,如慢性疼痛、焦慮和失眠。Delivra保健產品讓數百萬客户重新獲得了他們的機動性、能量和生活質量。該公司的兩個子公司的網站是 Dream Water™和 LivRelipmentTM。欲瞭解更多信息,請訪問 。

Non-IFRS Measures, Reconciliation and Discussion

非《國際財務報告準則》的計量、對賬和討論

This press release contains references to "Adjusted EBITDA" which is a non-IFRS financial measure. Adjusted EBITDA is a measure of the Company's loss from operations before interest, taxes, depreciation, and amortization and adjusted for share-based compensation, common shares issued for services, fair value effects of accounting for biological assets and inventories, asset impairment and write-downs, and other non-cash items, and is a non-IFRS measure.

本新聞稿提及“調整後的EBITDA”,這是一項非“國際財務報告準則”的財務措施。調整後的EBITDA是對公司在扣除利息、税項、折舊和攤銷前的運營虧損的衡量,並根據基於股份的補償、為服務發行的普通股、生物資產和庫存會計的公允價值影響、資產減值和減記以及其他非現金項目進行調整,是一種非國際財務報告準則的衡量標準。

This measure can be used to analyze and compare profitability among companies and industries, as it eliminates the effects of financing and capital expenditures. It is often used in valuation ratios and can be compared to enterprise value and revenue. This measure does not have any standardized meaning according to IFRS and, therefore, may not be comparable to similar measures presented by other companies.

這一衡量標準可用於分析和比較公司和行業之間的盈利能力,因為它消除了融資和資本支出的影響。它經常用於估值比率,可以與企業價值和收入進行比較。根據《國際財務報告準則》,這一措施沒有任何標準化意義,因此可能無法與其他公司提出的類似措施相比較。

There are no comparable IFRS financial measures presented in Delivra Health's financial statements. Reconciliations of the supplemental non-IFRS measure are presented in the Company's Management Discussion and Analysis for the three months ended September 30, 2022. This non-IFRS financial measure is presented because management has evaluated the financial results both including and excluding the adjusted items and believes that the non-IFRS financial measure presented provides additional perspective and insights when analyzing the core operating performance of the business. The Company believes that the supplemental measure provides information which is useful to shareholders and investors in understanding the Company's performance and may assist in the evaluation of the Company's business relative to that of its peers.

Delivra Health的財務報表中沒有提出類似的“國際財務報告準則”財務措施。在截至2022年9月30日的三個月的公司管理層討論和分析中介紹了非國際財務報告準則補充措施的對賬情況。提出這一非國際財務報告準則財務指標是因為管理層評估了包括和不包括調整後項目的財務結果,並相信提出的非國際財務報告準則財務指標在分析企業的核心經營業績時提供了額外的視角和洞察力。本公司相信,該補充措施提供對股東及投資者有用的資料,有助他們瞭解本公司的表現,並可協助評估本公司相對於其同業的業務。

The non-IFRS financial measure should not be considered superior to, as a substitute for, or as an alternative to, and should be considered in conjunction with the IFRS financial measures presented in the Company's financial statements. For more information, please see "Adjusted EBITDA (non-IFRS measure)" and "Non-IFRS Measures" in the Company's Management Discussion and Analysis for the three months ended September 30, 2022, which is available under the Company's profile on .

非《國際財務報告準則》財務措施不應被視為優於、替代或替代公司財務報表中列報的《國際財務報告準則》財務措施,並應與之一併考慮。欲瞭解更多信息,請參閲公司截至2022年9月30日的三個月的管理討論和分析中的“調整後的EBITDA(非國際財務報告準則計量)”和“非國際財務報告準則計量”,可在公司簡介下查閲。

Notes:

備註:

  1. This is a non-IFRS reporting measure. For a reconciliation of this measure to the nearest IFRS measure, see "Adjusted EBITDA (non-IFRS measure)" and "Non-IFRS Measures" in the Company's Management Discussion and Analysis for the three months ended September 30, 2022.
  1. 這是一項非國際財務報告準則的報告措施。關於這一計量與最近的國際財務報告準則計量的對賬,請參閲公司截至2022年9月30日的三個月的管理討論和分析中的“調整後的EBITDA(非國際財務報告準則計量)”和“非國際財務報告準則計量”。

Cautionary Note Regarding Forward-Looking Statements

有關前瞻性陳述的注意事項

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements include, among other things, statements with respect to the Company's growth objectives, increasing revenues and profitability, growth in new markets, and new distribution partners.

本新聞稿包含適用於加拿大證券法的“前瞻性信息”和“前瞻性陳述”(統稱為“前瞻性陳述”)。除有關歷史事實的陳述外,所有陳述均為前瞻性陳述,均基於截至本新聞稿發佈之日的預期、估計和預測。任何涉及關於預測、期望、信念、計劃、預測、目標、假設、未來事件或業績的討論的陳述(經常但不總是使用諸如“預期”或“不預期”、“預計”、“預期”或“不預期”、“計劃”、“預算”、“預定”、“預測”、“估計”、“相信”或“打算”或這些詞語和短語的變體,或陳述某些行動、事件或結果“可能”或“可能”、“將”,“可能”或“將”被視為發生或實現)不是歷史事實的陳述,可能是前瞻性陳述。在本新聞稿中,前瞻性陳述包括與公司的增長目標、增加收入和盈利能力、新市場的增長以及新的分銷合作伙伴有關的陳述。

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the cannabis markets where the Company operates; changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; employee relations and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution, and sale of cannabis and cannabis-related products in the markets where the Company operates. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

這些前瞻性陳述是基於作出這些陳述時公司管理層的合理假設和估計。由於前瞻性陳述涉及已知和未知的風險、不確定因素和其他因素,可能導致公司的實際結果、業績或成就與此類前瞻性陳述明示或暗示的未來結果、業績或成就大不相同,因此未來的實際結果可能大不相同。這些因素包括:新冠肺炎疫情對公司業務的影響;宏觀經濟形勢的總體波動;證券市場的波動;對公司經營的大麻市場規模的預期;消費者習慣的變化;公司成功實現業務目標的能力;擴張計劃;政治和社會不確定性;無法獲得足夠的保險以承保風險和危害;員工關係;以及存在可能對公司經營市場的大麻及大麻相關產品的種植、生產、分銷和銷售施加限制的法律法規。儘管本新聞稿中包含的前瞻性陳述是基於公司管理層認為或當時被認為是合理假設的,但公司不能向股東保證實際結果將與這些前瞻性陳述一致,因為可能存在其他因素導致結果與預期、估計或預期的結果不一致。讀者不應過分依賴本新聞稿中包含的前瞻性陳述和信息。如果信念、意見、預測或其他因素髮生變化,公司不承擔更新前瞻性陳述的義務, 除法律另有規定外。

Additional information regarding this and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated March 2, 2021, and under the heading "Risks and Uncertainties" in the Company's management's discussion and analysis dated October 28, 2022, for the year ended June 30, 2022, filed under the Company's profile on SEDAR at .

有關這一風險和與公司業務有關的其他風險和不確定因素的更多信息,載於公司日期為2021年3月2日的公司年度信息表中的“風險因素”標題,以及公司管理層於2022年10月28日提交的截至2022年6月30日的年度討論和分析中的“風險和不確定因素”標題下。

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.

多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所-V的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

Investor Relations:
Jack Tasse
Chief Financial Officer
IR@delivrahealth.com
1-877-915-7934

投資者關係:
傑克·塔斯
首席財務官
郵箱:ir@delivraHealth.com
1-877-915-7934

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論